Nanotechnology in Amyloid Lateral Sclerosis (ALS) - review

Agata Rocka, Dominika Psiuk, Faustyna Piędel, Klaudia Żak, Agnieszka Brzezińska



Introduction and purpose: Amyloid Lateral Sclerosis (ALS) is progressive, cachectic neurodegenerative disease. The lack of effective therapy, which could prevent disease progression and minimize degeneration of motor neurons, contributes to unceasing exploration for novel therapeutic methods. Nanotechnology remains one of the most promising areas among novel agents in neurodegenerative diseases treatment. Recent studies have shown that application of nanoparticles for drug delivery might develop greater effects in ALS treatment.The aim of the study is to analyze literature (database PubMed) for potential nanotechnology usage in ALS therapy.

A brief description of the state of knowledge: Nanotechnology is one of the most promising agent in many aspects of medicine, for example drug delivery, cancer therapy and wound healing. There are different kinds of nanoparticles for example gold, silver, metal-oxide, silica, lipid-based. There was one randomized clinical trial that used nanoparticles to improve bioavailability of turmeric, potential anti-inflammatory agent, in patients with ALS. This study showed that using nanoparticles is safe. Most of the recent analysis were carried out using animal models. Promising results were demonstrated in many studies.  

Conclusions: The available research confirms the usefulness of nanotechnology in increasing the effectiveness of ALS treatment. Animal studies have produced surprising results. Nanoparticles can improve the absorption of drugs and bioavailability, affecting the clinical improvement of patients, which gives new possibilities and therapeutic perspectives for patients with ALS. Personalized therapy based on using molecules and profund control of such therapy can greatly improve the effectiveness of treating people with ALS.


nanotechnology; nanoparticles; neurology; ALS

Full Text:



Orsini M, Oliveira AB, Nascimento OJ, Reis CH, Leite MA, de Souza JA, Pupe C, de Souza OG, Bastos VH, de Freitas MR, Teixeira S, Bruno C, Davidovich E, Smidt B. Amyotrophic Lateral Sclerosis: New Perpectives and Update. Neurol Int. 2015 Sep 24;7(2):5885.

Oskarsson B, Gendron TF, Staff NP. Amyotrophic Lateral Sclerosis: An Update for 2018. Mayo Clin Proc. 2018;93(11):1617-1628.

Kubiszewska J, Kwieciński H. Stwardnienie boczne zanikowe. Postępy Nauk Med 2010; 6: 440–448.

Logroscino G, Traynor BJ, Hardiman O, Chiò A, Mitchell D, Swingler RJ, Millul A, Benn E, Beghi E; EURALS. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2010 Apr;81(4):385-90.

Chiò A. et al. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology 41, 118–130 (2013).

Arthur KC, Calvo A, Price TR, Geiger JT, Chiò A, Traynor BJ. Projected increase in amyotrophic lateral sclerosis from 2015 to 2040. Nat Commun. 2016 Aug 11;7:12408. doi: 10.1038/ncomms12408. PMID: 27510634; PMCID: PMC4987527.

Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994;330(9):585-591.

Orrell R.W. Motor neuron disease: Systematic reviews of treatment for ALS and SMA. Br. Med. Bull. 2009;93:145–159.

Bhandari R, Kuhad A, Kuhad A. Edaravone: a new hope for deadly amyotrophic lateral sclerosis. Drugs Today (Barc). 2018;54(6):349-360.

Mazibuko Z, Choonara YE, Kumar P, et al. A review of the potential role of nano-enabled drug delivery technologies in amyotrophic lateral sclerosis: lessons learned from other neurodegenerative disorders. J Pharm Sci. 2015;104(4):1213-1229.

Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano. 2009;3(1):16-20.

Bayda S, Adeel M, Tuccinardi T, Cordani M, Rizzolio F. The History of Nanoscience and Nanotechnology: From Chemical-Physical Applications to Nanomedicine. Molecules. 2019;25(1):112. Published 2019 Dec 27.

Saeedi M, Eslamifar M, Khezri K, Dizaj SM. Applications of nanotechnology in drug delivery to the central nervous system. Biomed Pharmacother. 2019;111:666-675.

Xiang C, Zhang Y, Guo W, Liang XJ. Biomimetic carbon nanotubes for neurological disease therapeutics as inherent medication. Acta Pharm Sin B. 2020;10(2):239-248.

Saraf J, Kalia K, Bhattacharya P, Tekade RK. Growing synergy of nanodiamonds in neurodegenerative interventions. Drug Discov Today. 2019;24(2):584-594. doi:10.1016/j.drudis.2018.10.012

Vissers C, Ming GL, Song H. Nanoparticle technology and stem cell therapy team up against neurodegenerative disorders. Adv Drug Deliv Rev. 2019 Aug;148:239-251.

Male D, Gromnicova R, McQuaid C. Gold Nanoparticles for Imaging and Drug Transport to the CNS. Int Rev Neurobiol. 2016;130:155-198.

Swierczewska M, Lee S, Chen X. The design and application of fluorophore-gold nanoparticle activatable probes. Phys Chem Chem Phys. 2011;13(21):9929-9941.

Curry T, Kopelman R, Shilo M, Popovtzer R. Multifunctional theranostic gold nanoparticles for targeted CT imaging and photothermal therapy. Contrast Media Mol Imaging. 2014;9(1):53-61.

Aliev G, Daza J, Herrera AS, et al. Nanoparticles as Alternative Strategies for Drug Delivery to the Alzheimer Brain: Electron Microscopy Ultrastructural Analysis. CNS Neurol Disord Drug Targets. 2015;14(9):1235-1242.

Gonzalez-Carter DA, Leo BF, Ruenraroengsak P, et al. Silver nanoparticles reduce brain inflammation and related neurotoxicity through induction of H2S-synthesizing enzymes. Sci Rep. 2017;7:42871. Published 2017 Mar 2.

Tang J, Xiong L, Wang S, et al. Distribution, translocation and accumulation of silver nanoparticles in rats. J Nanosci Nanotechnol. 2009;9(8):4924-4932.

J. Skalska, L. Struzynska. Toxic effects of silver nanoparticles in mammals–does a risk. Folia Neuropathol 2015; 53 (4): 281-300.

Sintov AC, Velasco-Aguirre C, Gallardo-Toledo E, Araya E, Kogan MJ. Metal Nanoparticles as Targeted Carriers Circumventing the Blood-Brain Barrier. Int Rev Neurobiol. 2016;130:199-227.

Dowding JM, Song W, Bossy K, et al. Cerium oxide nanoparticles protect against Aβ-induced mitochondrial fragmentation and neuronal cell death. Cell Death Differ. 2014;21(10):1622-1632.

Hopkins LE, Patchin ES, Chiu PL, Brandenberger C, Smiley-Jewell S, Pinkerton KE. Nose-to-brain transport of aerosolised quantum dots following acute exposure. Nanotoxicology. 2014 Dec;8(8):885-93. doi: 10.3109/17435390.2013.842267. PMID: 24040866; PMCID: PMC3992067.

Dubertret B, Skourides P, Norris DJ, Noireaux V, Brivanlou AH, Libchaber A. In vivo imaging of quantum dots encapsulated in phospholipid micelles. Science. 2002;298(5599):1759-1762.

Guo JW, Guan PP, Ding WY, et al. Erythrocyte membrane-encapsulated celecoxib improves the cognitive decline of Alzheimer's disease by concurrently inducing neurogenesis and reducing apoptosis in APP/PS1 transgenic mice. Biomaterials. 2017;145:106-127.

Zhang B, Yan W, Zhu Y, et al. Nanomaterials in Neural-Stem-Cell-Mediated Regenerative Medicine: Imaging and Treatment of Neurological Diseases. Adv Mater. 2018;30(17):e1705694.

Tamaru M, Akita H, Nakatani T, et al. Application of apolipoprotein E-modified liposomal nanoparticles as a carrier for delivering DNA and nucleic acid in the brain. Int J Nanomedicine. 2014;9:4267-4276.

Cunha S, Amaral MH, Lobo JM, Silva AC. Therapeutic Strategies for Alzheimer's and Parkinson's Diseases by Means of Drug Delivery Systems. Curr Med Chem. 2016;23(31):3618-3631.

Zhang ZG, Chopp M. Exosomes in stroke pathogenesis and therapy. J Clin Invest. 2016 Apr 1;126(4):1190-7.

Ahmadi M, Agah E, Nafissi S, et al. Safety and Efficacy of Nanocurcumin as Add-On Therapy to Riluzole in Patients With Amyotrophic Lateral Sclerosis: A Pilot Randomized Clinical Trial. Neurotherapeutics. 2018;15(2):430-438.

Marcuzzo S, Isaia D, Bonanno S, et al. FM19G11-Loaded Gold Nanoparticles Enhance the Proliferation and Self-Renewal of Ependymal Stem Progenitor Cells Derived from ALS Mice. Cells. 2019;8(3):279.

DeCoteau W, Heckman KL, Estevez AY, et al. Cerium oxide nanoparticles with antioxidant properties ameliorate strength and prolong life in mouse model of amyotrophic lateral sclerosis. Nanomedicine. 2016;12(8):2311-2320.

Bushra Nabi, Saleha Rehman, Mohammad Fazil, Saba Khan, Sanjula Baboota & Javed Ali (2020) Riluzole-loaded nanoparticles to alleviate the symptoms of neurological disorders by attenuating oxidative stress, Drug Development and Industrial Pharmacy, 46:3, 471-483.

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM

Journal of Education, Health and Sport formerly Journal of Health Sciences

Declaration on the original version.

Editors indicates that the main version of the magazine is to issue a "electronic".

The journal has had 5 points in Ministry of Science and Higher Education parametric evaluation. § 8. 2) and § 12. 1. 2) 22.02.2019.

1223 Journal of Education, Health and Sport eISSN 2391-8306 7

ISSN 2391-8306 formerly ISSN: 1429-9623 / 2300-665X

Archives 2011 - 2014

PBN 2011 - 2014

POL-index 2011 - 2014

BASE 2011 - 2014

Indexed in Bases, Bazy indeksacyjne: ERIH Plus, Worldcat, PBN/POL-Index, ICI Journals Master List, Directory of Open Access Journals (DOAJ), ZBD, Ulrich's periodicals, Google Scholar, Polska Bibliografia Lekarska, EuroPub database, NLM Catalog Result - NCBI, BASE, Russian Sciences Index, Arianta.

US NLM = 101679844

101679844 - NLM Catalog Result - NCBI

Find a library that holds this journal:


PBN Poland



Redaction, Publisher and Editorial Office

Publisher and Editorial Office
Department of Physical Culture,
Faculty of Earth Sciences and Spatial Management,
Nicolaus Copernicus University in Toruń, Poland
Address: Str. Lwowska 1, 87-100 Toruń, Poland

  Open Access ISSN 2391-8306 formerly ISSN: 1429-9623 / 2300-665X

The journal has been approved for inclusion in ERIH PLUS.

The ERIH PLUS listing of the journal is available at

Indexed in Index Copernicus Journals Master List.,p24782242,3.html

ICV 2018 = 95.95 ICV 2017 = 91.30 ICV 2016 = 84.69 ICV 2015 = 93.34 ICV 2014 = 89.51 Standardized Value: 8.27 ICV 2013: 7.32 ICV 2012: 6.41 ICV 20115.48

RG Journal Impact: 0.18 *

*This value is calculated using ResearchGate data and is based on average citation counts from work published in this journal. The data used in the calculation may not be exhaustive.

RG Journal impact history

2020Available summer 2021
2018 / 20190.18

RG Journal impact over time

RG Journal impact

Indexed in Polish Scholarly Bibliography (PBN) (PBN Polska Bibliografia Naukowa) (

is a portal of the Polish Ministry of Science and Higher Education, collecting information on publications of Polish scientists and on Polish and foreign scholarly journals. Polish Scholarly Bibliograhpy is a part of POL-on - System of Information on Higher Education. It is operated by the Interdisciplinary Centre for Mathematical and Computational Modelling, University of Warsaw.

Indexed in Russian Sciences Index Российский индекс научного цитирования (РИНЦ)

Indexed in Arianta Polish scientific and professional electronic journals Aneta Drabek i Arkadiusz Pulikowski


Partnerzy platformy czasopism